The journal brings readers the latest developments in the fast moving field of cellular therapy in man. This includes cell therapy for cancer, immune disorders, inherited diseases, tissue repair and regenerative medicine. The journal covers the science, translational development and treatment with variety of cell types including hematopoietic stem cells, immune cells (dendritic cells, NK, cells, T cells, antigen presenting cells) mesenchymal stromal cells, adipose cells, nerve, muscle, vascular and endothelial cells, and induced pluripotential stem cells. We also welcome manuscripts on subcellular derivatives such as exosomes. A specific focus is on translational research that brings cell therapy to the clinic. Cytotherapy publishes original papers, reviews, position papers editorials, commentaries and letters to the editor. We welcome "Protocols in Cytotherapy" bringing standard operating procedure for production specific cell types for clinical use within the reach of the readership.

《Cytotherapy》是一本由ELSEVIER SCI LTD出版商出版的专业医学期刊，该刊创刊于1999年，刊期Bimonthly，该刊已被国际权威数据库SCIE收录。在中科院最新升级版分区表中，该刊分区信息为大类学科：医学 2区，小类学科：生物工程与应用微生物 2区；细胞与组织工程 3区；细胞生物学 3区；血液学 3区；医学：研究与实验 3区；在JCR（Journal Citation Reports）分区等级为Q1。该刊发文范围涵盖生物工程与应用微生物等领域，旨在及时、准确、全面地报道国内外生物工程与应用微生物工作者在该领域取得的最新研究成果、工作进展及学术动态、技术革新等，促进学术交流，鼓励学术创新。2021年影响因子为6.196，平均审稿速度偏慢,4-8周。